NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $19.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. Ascendiant Capital Markets increased their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. D. Boral Capital restated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a report on Monday, March 17th.

NRx Pharmaceuticals Trading Up 0.5 %

NRXP opened at $2.08 on Thursday. The stock has a 50-day moving average price of $2.82 and a 200-day moving average price of $2.03. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The stock has a market capitalization of $35.19 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, equities research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Townsquare Capital LLC bought a new position in NRx Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at approximately $33,000. Squarepoint Ops LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at approximately $56,000. Millennium Management LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at approximately $61,000. Finally, Anson Funds Management LP bought a new position in NRx Pharmaceuticals during the 3rd quarter valued at approximately $241,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.